SMMT Summit Therapeutics PLC

$26.29

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 8/18/2025

About Summit Therapeutics PLC

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and markets drugs to treat infectious diseases in the United States, Latin America, and Europe. The company is headquartered in Cambridge, Massachusetts.

Website: https://www.summittxinc.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1599298
Address
136A EASTERN AVENUE, MILTON PARK, ABINGDON, GB
Valuation
Market Cap
$18.15B
P/E Ratio
nan
PEG Ratio
0.00
Price to Book
46.70
Performance
EPS
$-0.31
Dividend Yield
—
Profit Margin
0.00%
ROE
-94.90%
Technicals
50D MA
$20.12
200D MA
$18.00
52W High
$33.89
52W Low
$2.10
Fundamentals
Shares Outstanding
738M
Target Price
$35.41
Beta
-0.46

SMMT EPS Estimates vs Actual

● Estimated
● Actual

SMMT News & Sentiment

Aug 17, 2025 • Motley Fool SOMEWHAT-BULLISH
3 Fantastic Growth Stocks to Buy in August
Only one of these growth stocks is up big so far in 2025. But all three could be huge winners over the next few years.
Aug 12, 2025 • Zacks Commentary SOMEWHAT-BULLISH
SMMT Q2 Loss Wider Than Expected, Ivonescimab Studies in Focus
Summit Therapeutics posts wider-than-expected second-quarter loss as ivonescimab trials advance in multiple lung cancer settings.
Aug 11, 2025 • Zacks Commentary NEUTRAL
Merck Stock Down 4% Since Q2 Results: How to Play the Stock
Merck slips following its Q2 results as Gardasil sales slump. However, Keytruda, new launches and a rich pipeline bolster its long-term case.
Aug 03, 2025 • Motley Fool SOMEWHAT-BULLISH
2 Beaten-Down Stocks With Incredible Upside Potential
Getting in on the ground floor with these companies might lead to superior returns.
Jul 31, 2025 • CNBC NEUTRAL
Pandemic darlings Moderna, BioNTech are now on two different paths
The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find themselves on different paths.
Jul 25, 2025 • Zacks Commentary NEUTRAL
Merck Q2 Earnings in the Cards: Buy, Sell or Hold Ahead of Results?
MRK is gearing up to report Q2 earnings. While Keytruda drives growth, there are concerns over Gardasil's China sales, generics and pipeline depth.
Sentiment Snapshot

Average Sentiment Score:

0.123
50 articles with scored sentiment

Overall Sentiment:

Neutral

SMMT Reported Earnings

Apr 29, 2025
Mar 31, 2025 (Pre market)
0.0 Surprise
  • Reported EPS: $0.00
  • Estimate: $0.00
  • Whisper: —
  • Surprise %: 0.0%
Dec 31, 2024
Dec 31, 2024 (Pre market)
-0.0 Surprise
  • Reported EPS: $-0.06
  • Estimate: $-0.06
  • Whisper: —
  • Surprise %: -3.3%
Oct 30, 2024
Sep 30, 2024 (Pre market)
-0.01 Surprise
  • Reported EPS: $-0.08
  • Estimate: $-0.07
  • Whisper: —
  • Surprise %: -14.3%
Aug 06, 2024
Jun 30, 2024 (Pre market)
-0.03 Surprise
  • Reported EPS: $-0.09
  • Estimate: $-0.06
  • Whisper: —
  • Surprise %: -50.0%
May 01, 2024
Mar 31, 2024 (Pre market)
0.0 Surprise
  • Reported EPS: $-0.06
  • Estimate: $-0.06
  • Whisper: —
  • Surprise %: 0.0%
Feb 20, 2024
Dec 31, 2023 (Pre market)
0.0 Surprise
  • Reported EPS: $-0.05
  • Estimate: $0.00
  • Whisper: —
  • Surprise %: 0.0%
Nov 07, 2023
Sep 30, 2023 (Pre market)
0.0 Surprise
  • Reported EPS: $-0.03
  • Estimate: $0.00
  • Whisper: —
  • Surprise %: 0.0%
Aug 09, 2023
Jun 30, 2023 (Pre market)
0.0 Surprise
  • Reported EPS: $-0.02
  • Estimate: $0.00
  • Whisper: —
  • Surprise %: 0.0%
May 11, 2023
Mar 31, 2023 (Pre market)
0.0 Surprise
  • Reported EPS: $-1.43
  • Estimate: $0.00
  • Whisper: —
  • Surprise %: 0.0%

Financials